News

Select Year
Thank you! Your submission has been received!
Oops! Something went wrong while submitting the form.
January 6, 2023 6:00 AM
EST
2023
Aurinia Provides Preliminary Unaudited Fourth Quarter and Full-year 2022 Net Revenue Results
Download
January 4, 2023 4:05 PM
EST
2023
Aurinia Pharmaceuticals to Present at Upcoming 41st Annual J.P. Morgan Healthcare Conference
Download
January 3, 2023 4:55 PM
EST
2023
Aurinia Reports New Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
Download
January 3, 2023 9:12 AM
EST
2023
Aurinia Announces LUPKYNIS® (voclosporin) Patent Challenge Settlement Reached With Sun Pharmaceuticals
Download
December 5, 2022 4:05 PM
EST
2022
Aurinia Reports New Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
Download
December 5, 2022 2:35 AM
EST
2022
Aurinia Reports New Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
Download
November 30, 2022 4:05 PM
EST
2022
Aurinia Announces the Great Britain Marketing Authorization of LUPKYNIS® (voclosporin) for the Treatment of Lupus Nephritis
Download
November 3, 2022 6:00 AM
EDT
2022
Aurinia Reports Third Quarter and Nine Months 2022 Financial and Operational Results
Download
October 28, 2022 5:30 PM
EDT
2022
Aurinia Pharmaceuticals to Release Third Quarter 2022 Financial and Operational Results on November 3, 2022
Download
October 27, 2022 12:00 PM
EDT
2022
Aurinia Pharmaceuticals Announces Presentations at American Society of Nephrology (ASN) Kidney Week 2022
Download
October 25, 2022 7:05 AM
EDT
2022
Aurinia Launches Campaign Aimed at Educating and Motivating People with Lupus Nephritis to Prioritize Their Kidney Health and Take Action
Download
October 3, 2022 4:05 PM
EDT
2022
Aurinia Reports New Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
Download
September 20, 2022 4:05 PM
EDT
2022
Aurinia Pharmaceuticals Announces Presentations at American College of Rheumatology (ACR) Convergence 2022
Download
September 19, 2022 11:15 AM
EDT
2022
Aurinia Announces European Commission Approval of LUPKYNIS® (voclosporin) for the Treatment of Lupus Nephritis
Download
August 4, 2022 6:00 AM
EDT
2022
Aurinia Reports Second Quarter and Six Months 2022 Financial and Operational Results
Download
August 1, 2022 4:05 PM
EDT
2022
Aurinia Reports New Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
Download
July 26, 2022 2:00 PM
EDT
2022
Aurinia Pharmaceuticals Notification Regarding Inter Partes Patent Review
Download
July 25, 2022 4:07 PM
EDT
2022
Aurinia Pharmaceuticals to Release Second Quarter 2022 Financial and Operational Results on August 4, 2022
Download
July 22, 2022 6:05 AM
EDT
2022
Aurinia Announces Positive CHMP Opinion for LUPKYNIS® (voclosporin) for the Treatment of Adults with Active Lupus Nephritis in Europe
Download
July 14, 2022 4:10 PM
EDT
2022
Aurinia Announces the Addition of Three Seasoned Executive Leaders to Advance Company Strategy and Performance
Download
June 6, 2022 4:05 PM
EDT
2022
Aurinia Reports New Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
Download
June 3, 2022 7:05 AM
EDT
2022
Aurinia Presents Data Demonstrating LUPKYNIS® (voclosporin) is Effective in Achieving Proteinuria Treatment Targets in Lupus Nephritis Defined by EULAR/ERA Recommendations
Download
May 20, 2022 12:07 PM
EDT
2022
Aurinia Presents Results from the Two-Year AURORA 2 Continuation Study at the 2022 European Renal Association (ERA) Congress
Download
May 16, 2022 7:17 AM
EDT
2022
Aurinia Pharmaceuticals Announces Presentations at the 2022 ERA Congress and the 2022 EULAR Congress
Download
May 10, 2022 6:00 AM
EDT
2022
Aurinia Reports First Quarter 2022 Financial and Operational Results
Download
No Results Found
Please try different keywords or filters.

Email Alerts

By providing your email address above, you are providing consent to Aurinia Pharmaceuticals Inc. to send you the requested Investor Email Alert updates. For information on how we protect your information, please refer to our Privacy Policy.
Thank you! Your message has been sent!
Oops! There was an error with your submission.